Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01557686
Other study ID # H-4-2010-046 Pilot
Secondary ID
Status Completed
Phase Phase 0
First received March 15, 2012
Last updated March 16, 2012
Start date May 2010
Est. completion date February 2011

Study information

Verified date March 2012
Source Universitetshospitalernes Center for Sygepleje
Contact n/a
Is FDA regulated No
Health authority Denmark: The Danish National Committee on Biomedical Research Ethics
Study type Interventional

Clinical Trial Summary

The purpose of this pilot study is to test an exercise-based multidimensional intervention for patients with acute leukaemia undergoing consolidation chemotherapy in the context of outpatient management. Further, to test for safety, feasibility and preliminary effect on physical and functional capacity, and health related quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date February 2011
Est. primary completion date February 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients that are able to speak Danish > 18 years and newly diagnosed with acute leukæmia (MDS, AML, CMML, APL or ALL)

- Normal EKG, blood pressure and pulse

- Signed informed written consent

Exclusion Criteria:

- Medical reason that contraindicates physical activity

- Patients diagnosed with a symptomatic cardiac disease within the last three months.

- Documented bone metastasis

- Dementia, psychotic

- Cannot write or read Danish

- Patients unable to carry out baseline tests

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Behavioral:
Health counseling and exercise
The intervention is initiated during chemotherapy treatment (consolidation) in the outpatient clinic and continues for 6 weeks. The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and two health-promoting counseling sessions - Further, patients are fitted with a step counter pedometer.

Locations

Country Name City State
Denmark Copenhagen University Hospital Copenhagen
Denmark Herlev Hospital Herlev

Sponsors (3)

Lead Sponsor Collaborator
Universitetshospitalernes Center for Sygepleje Lundbeck Foundation, Novo Nordisk A/S

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility - adherence rates Percentage of intervention participation Adherence to the intervention components from baseline to 6 weeks Yes
Secondary Adverse events Number and type of adverse events baseline to 6 weeks Yes
Secondary 6MWD Change in distance in meter Change from baseline in 6MWD at 6 weeks Yes
Secondary Attrition Number of patients that withdrew from the project Withdrawal from the project from baseline to 6 weeks Yes
Secondary Timed chair stand Change in the number of repetitions Change from baseline in timed chair stand at 6 weeks Yes
Secondary Timed bicep curl Change in number of repetitions Change from baseline in timed bicep curl at 6 weeks Yes
Secondary FACT-Anemia Change in scores for quality of life/function Change from baseline in FACT-An at 6 weeks No
Secondary HADS Change in scores for emotional wellbeing Change from baseline in HADS at 6 weeks No
Secondary SF36 Change in scores for general health Change from baseline in SF36 at 6 weeks No
Secondary MDSAI Change in scores for symptom burden Change from baseline over time (1,2,3,4,5,6 weeks) No
See also
  Status Clinical Trial Phase
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Active, not recruiting NCT01956630 - Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT Phase 1/Phase 2
Completed NCT00988013 - Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies N/A
Enrolling by invitation NCT01728402 - Pathogenesis of Hematologic Malignancies
Active, not recruiting NCT03595800 - Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen Phase 3
Completed NCT02440178 - Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia Phase 2
Recruiting NCT05071482 - Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL Phase 4
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Completed NCT03042676 - Electronic Database for the Follow up of the ATG_FamilyStudy
Completed NCT04597086 - Bright White Light Therapy for the Improvement of Sleep, Fatigue, Distress, Depression, and Anxiety in Hospitalized Leukemia Patients N/A
Terminated NCT03588936 - Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant Phase 1
Recruiting NCT05521204 - Olverembatinib for FGFR1-rearranged Neoplasms Phase 2
Not yet recruiting NCT04084327 - Immunophenotyping of Acute b Cell Lymphoblstic Leukemia
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Not yet recruiting NCT06026839 - Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors